ReNeuron
10 Nugent Road
Surrey Research Park
Guildford
Surrey
GU27AF
United Kingdom
Tel: 44-0-1483-302560
Fax: 44-0-1483-534864
Website: http://www.reneuron.com/
Email: info@reneuron.com
100 articles about ReNeuron
-
ReNeuron Signs New Exosome Research Collaboration
6/25/2020
ReNeuron Group plc announced that it has signed a new research evaluation agreement with a major U.S. biotechnology company in connection with the use of the Company's proprietary exosomes for the delivery of novel gene silencing therapeutics.
-
ReNeuron Provides Program and Regulatory Approvals Update
6/17/2020
ReNeuron Group plc, a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programs.
-
ReNeuron Announces CTX Cell Line Shows Further Potential
5/7/2020
Newly Published Positive Efficacy Data in an Accepted Model of Huntington's Disease
-
ReNeuron Announces Exosome Research Collaboration
4/7/2020
ReNeuron Group plc announced that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company's proprietary exosomes to deliver novel therapeutics.
-
ReNeuron Update Regarding COVID-19
4/6/2020
ReNeuron Group plc, a global leader in the development of cell-based therapeutics, provides the following update in light of the COVID-19 pandemic and the effect on the Company of U.K. and U.S. government measures to contain the spread of the disease..
-
ReNeuron Announces Publication of Positive Phase 2a Stroke Clinical Data
2/18/2020
ReNeuron Group plc, a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.
-
ReNeuron Presents Positive Data at the 27th Annual Congress of the European Society of Gene and Cell Therapy on Lead Cell Line
10/23/2019
New data show ReNeuron's lead CTX cell therapy candidate can be re-programmed into a pluripotent state and differentiated into other cell types
-
Clinical Catch-Up: October 14-18
10/21/2019
Last week was busy for clinical trial news. Here’s a look. -
ReNeuron Presents Positive Clinical Data at the American Academy of Ophthalmology Annual Meeting
10/14/2019
Study investigator presents positive efficacy data in ongoing retinal disease clinical trial
-
ReNeuron Announces Clinical Update and Conference Presentations
10/2/2019
"Clear efficacy signal" in Phase 2a study of hRPC cell therapy in retinitis pigmentosa
-
ReNeuron Expands Exosome IP Portfolio with Key Patent Grants
7/16/2019
ReNeuron Group plc, a UK-based global leader in the development of cell-based therapeutics, announced that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.
-
ReNeuron to Participate in the Jefferies 2019 Global Healthcare Conference
5/31/2019
ReNeuron Group plc announced that ReNeuron's management team will participate in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 in New York City.
-
ReNeuron Provides Business Update and Results Notification
5/8/2019
Second Cohort of Phase 2a Study in Retinitis Pigmentosa Dosing Complete
-
ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Study at the Sixth Annual Retinal Cell and Gene Therapy Innovation Summit
4/26/2019
hRPC Cell Therapy Demonstrates Sustained and Further Improvement in Vision at 60 and 120 Days in First Cohort of Phase 2a study in Retinitis Pigmentosa
-
ReNeuron Partners with Fosun Pharma in China
4/9/2019
ReNeuron to receive upfront, near term and estimated success-based milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on sales
-
ReNeuron to Present at the H.C. Wainwright Global Life Sciences Conference
4/5/2019
ReNeuron Group plc announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 3:30 p.m. BST at the Grosvenor House in London.
-
ReNeuron to Present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day
3/18/2019
ReNeuron Group plc announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day on Thursday, March 21, 2019 at 9:10 am ET at The Metropolitan Club in New York City.
-
ReNeuron Announces Retinal Clinical Trial Progresses to Next Stage
3/18/2019
ReNeuron Group plc is pleased to announce a further update on progress with the ongoing Phase I/II clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
-
ReNeuron Group plc Announces Positive Preliminary Data in U.S. Retinitis Pigmentosa Trial
2/20/2019
hRPC Cell Therapy Demonstrates Significant Restoration of Vision in First Cohort of Phase 2 Study in Retinitis Pigmentosa
-
ReNeuron Release: Reports Positive Results In Phase II Stroke Trial
12/5/2016